PRNewsWire
10 Aug 2026, 07:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities fraud class action lawsuit alleging the use of channel stuffing to artificially inflate revenue. — Allegations of revenue manipulation via channel stuffing typically lead to severe loss of investor trust and potential downward revisions of financial performance.
-0.80The lawsuit claims ADMA failed to disclose a related party transaction and lacked appropriate internal controls. — Failures in internal controls and undisclosed related party transactions suggest systemic governance issues and increase the risk of further regulatory scrutiny.
-0.60The class period for the alleged fraud spans from August 9, 2024, to March 25, 2026. — Defining the class period identifies the timeframe of suspected misinformation, though it is less impactful than the nature of the fraud itself.
-0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
